Vertex Pharmaceuticals Increase (decrease) in amount of unrecognized tax benefits remained flat by 0.0% to $36.48M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 61.6%, from $22.58M to $36.48M. Over 2 years (FY 2023 to FY 2025), Increase (decrease) in amount of unrecognized tax benefits shows relatively stable performance with a -3.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests higher tax uncertainty or aggressive tax planning, while a decrease suggests resolution of past uncertainties.
This represents the net change in the total reserve for uncertain tax positions during the reporting period. It reflects...
Standard disclosure under ASC 740 regarding uncertain tax positions.
other_unrecognized_tax_benefits_period_increase_decrease| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $156.30M | $90.30M | $145.90M |
| YoY Change | — | -42.2% | +61.6% |